41 results about "Retinal ischemia" patented technology

A battery powered, hand held device to determine of there is significant retinal ischemia in the eye of a patient. The device detects the consequences of impaired blood flow in the eye of the patient and has a light source for emitting a light and a diffuser or diffuse spheroidal reflector that redirects the light from the light source toward the patient's eye. A set of electrodes contact the patients skin proximate to the eye and receives an electrical signal representing the eye's electrical response to the light stimulus. A microcontroller interprets the electrical signal sensed by the electrodes by using an algorithm to determine the degree of retinal ischemia of the patient. In one embodiment, there is a control that establishes the intensity of the light stimulus by measuring and using the area of the pupil.

A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory diseases, and the like in mammals.

The present invention provides a treatment for promoting beneficial physiological revascularization of ischemic retinal tissue. The treatment comprises administering to a mammal suffering from a retinal vascular ischemia a therapeutically effective amount of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS), thereby simultaneously inhibiting pathological neovascularization while promoting beneficial physiological revascularization of damaged areas of the retina. In a preferred embodiment, the angiostatic fragment of TrpRS is T2-TrpRS or T2-TrpRS-GD. Preferably, the mammal is a human patient suffering from retinal ischemia.

The present invention relates to methods of treating retinopathy, retinal ischemia and / or retinal edema comprising administering an integrin or integrin subunit antagonist, leukocyte adhesion-inducing cytokine antagonist or growth factor antagonist, a selectin antagonist or adhesion molecule antagonist.

The present invention relates to the use of hydroxycarbamide (HC) for reducing and / or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

The invention belongs to the field of pharmacy, and particularly relates to a use of leonurine in preparing a retina and optic nerve protection drug, in particular to a use in preparing a drug for treating retinal vascular diseases, optic nerve inflammation and degenerative changes. In the use, by virtue of an anterior chamber normal saline perfusion induced retinal ischemia reperfusion injury model experiment, a result shows the leonurine can reduce the apoptosis of the ischemia reperfusion injured RGCs, can increase the survival rate of the RGCs, can alleviate the thinning degree of the ischemia reperfusion injured retina and has an effect for protecting various layers of the retina; and the leonurine can be prepared into a drug for treating the retina injured diseases, the drug can be used for treating the retinal ischemia reperfusion injury, the retinal and optic nerve degenerative diseases, and used for treating the retinal inflammation diseases by adjusting the inflammation reaction of eyes. A new therapeutic drug is provided for clinically treating the eye diseases.

The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5′-diphospho-ribose) polymerase [“poly(ADP-ribose) polymerase” or “PARP”, which is also sometimes called “PARS” for poly(ADP-ribose) synthetase]. More particularly, the invention relates to the use of PARP inhibitors to prevent and / or treat tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury; neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and / or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells.

RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.